PT -期刊文章盟-弗朗西斯科·萨加盟特蕾莎修女Costabile AU -安东尼奥Carotenuto AU -罗伯塔Lanzillo盟-马塞洛默西亚最过硬AU -奇亚拉窗格盟Cinzia也好Russo AU -安娜玛丽亚Barbarulo盟莎拉Casertano Elisabetta Signoriello AU -菲比安娜罗西盟盟- Giacomo逻辑单元盟Vincenzo布雷西亚猜拳TI - eds集成的简短的国际认知评估多发性硬化症和取向测试(P4.333) DP - 2017年4月18日TA -神经病学PG - P4.333 VI - 88 IP - 16补充4099 - //www.ez-admanager.com/content/88/16_Supplement/P4.333.short 4100 - //www.ez-admanager.com/content/88/16_Supplement/P4.333.full所以Neurology2017 4月18日;首页88 AB -目的:我们研究的目的是提出一个快速和客观的方法来测量大脑的功能评分(CFS)扩大残疾状态量表(eds),并评估其影响最后eds分数有一大群人的MS患者。背景:认知障碍影响了约40 - 60%的女士,并包括所有疾病亚型和进步往往随着时间的推移,有时独立于身体残疾的积累。尽管认知测试验证在多发性硬化症(MS),神经心理学的评估是没有实现的评价慢性疲劳综合症。设计/方法:我们使用了短暂的国际认知评估(BICAMS)女士和取向测试(OTs)来衡量CFS得分,并评估其对eds的影响。我们比较eds照常计算(Native-EDSS)和后使用BICAMS和OT (NPS-EDSS)。结果:我们测试了604 MS患者BICAMS, OTs和eds。384名患者(63.6%)至少有一个在BICAMS改变测试。native-EDSS年长的年龄,受教育程度较低,高,和男性性别、独立与至少一个受损BICAMS测试。Native-EDSS不同于NPS-EDSS(0.001−0.112;术中)99例(16%)。当考虑患者Native-EDSS≤4.0,计算错误eds的比例是25%。结论:使用简短的神经心理学测试导致更准确的CFS评估在三分之二的病人,女士和更准确的eds计算25%的患者评分≤4.0。 This may help clinicians to better recognize cognitive impairment in everyday clinical practice, especially in the case of isolated cognitive worsening.Study Supported by: The study did not receive any support.Disclosure: Dr. Sacca has received personal compensation activities with Novartis, Almirall, Genzyme, and TEVA a speaker, editorial work, and advisory boards. Dr. Costabile has nothing to disclose. Dr. Carotenuto has nothing to disclose. Dr. Lanzillo has received personal compensation from Novartis, Almirall, Genzyme, Merk Serono, Biogen, and TEVA for public speaking, editorial work and advisory boards. Dr. Moccia has received personal compensation for activities with Sanofi Genzyme as an employee. Dr. Pane has nothing to disclose. Dr. Russo has nothing to disclose. Dr. Barbarulo has nothing to disclose. Dr. Casertano has nothing to disclose. Dr. Rossi has nothing to disclose. Dr. Signoriello has nothing to disclose. Dr. Lus has received personal compensation for activities with Biogen, Merk Serono, Bayer, Genzyme, Almirall, Novartis, and TEVA for speaking and advisory boards. Dr. Brescia Morra has received personal compensation for activities with Biogen, Merk Serono, Bayer, Genzyme, Almirall, Novartis, and Teva Neuroscience as a speaker and a member of an advisory board.